Know the actual treatment and new therapies in mRCC. Recognize the molecular basis behind novel anticancer agents in mRCC and how affects radiological response. Describe typical and atypical radiologic response with the use of TAT in mRCC
Renal cell carcinoma (RCC) account for 4% of all adult malignancies.
RCC is classificated in clear cell (80%),
chromophobe and other less common histologic types.
About 65% of patients have localized tumours (stage I,
II and III),
which are treated with partial or total nephrectomy.
On the other hand,
35% of patients who present with metastatic RCC (mRCC) or with relapse require systemic treatment. The systemic first-line treatment in the past decade was Interleukin-2 (IL-2)...
Findings and procedure details
Molecular basis of RCC treatment VHL is a tumour suppressor gene identified in familiar studies of VHL syndrome.
This group is identified in >90% of VHL mutations in spontaneous clear cell RCCs.
VHL is an E3 ubiquitin ligase that regulates a number of pro-angiogenic factors for degradation,
including vascular endothelial growth factor (VEGF).
Mutations that cause loss or silencing of VHL result in activation of these pro-angiogenic factors.
Identification of these mechanisms has led to the...
Recent advances in the therapy of renal carcinoma have extended the role of radiologist in patients with metastatic RCC.
Knowledge about TAT and recognize the patterns of response is essential for correct assessment in this patients.
CA Cancer J Clin 2015;65(1):5–29. Hirsch MS,
Dal Cin P.
Adult renal cell carcinoma: a review of established entities from morphology to molecular genetics.
Surg Pathol Clin 2015;8(4):587–621. Srigley JR,
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.
Am J Surg Pathol 2013;37(10):1469–1489. Brufau BP,